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Abstract: The hepatopulmonary syndrome is characterized as the triad of liver disease, 
pulmonary gas exchange abnormalities leading to arterial deoxygenation and evidence of 
intrapulmonary vascular dilatations. This review summarizes the pathological mechanisms 
leading to pulmonary vascular changes in hepatopulmonary syndrome. The role of the three 
currently used diagnostic imaging modalities of contrast-enhanced echocardiography, perfusion 
lung scanning and pulmonary arteriography that identify the presence of intrapulmonary vascular 
abnormalities are reviewed. Liver transplantation is considered to be the deﬁ  nitive treatment of 
hepatopulmonary syndrome with often successful reversal of hypoxemia, however other treat-
ments have been trialed. This review further appraises the evidence for the use of pharmacological 
agents and the role of radiological interventions in hepatopulmonary syndrome.
Keywords: hepatopulmonary syndrome, liver cirrhosis, lung diseases
Hepatopulmonary syndrome
Hepatopulmonary syndrome (HPS) is deﬁ  ned as the triad of liver disease, pulmonary 
gas exchange abnormalities leading to arterial deoxygenation, and evidence of 
intrapulmonary vascular dilatations (Krowka 2000). The prevalence in the setting 
of cirrhosis varies from 4% (Stoller et al 1995) to 47% (Hopkins et al 1992). This 
disparity in prevalence rates can be attributed to different cut-offs in deﬁ  ning arterial 
hypoxemia in primary studies. HPS is a pulmonary vascular disorder responsible for 
an increased morbidity and mortality among patients awaiting liver transplantation 
(Swanson et al 2005).
A relationship between the liver and the lung was ﬁ  rst noted by Fluckiger (1884) 
based on his observation of a woman with cirrhosis, cyanosis, and clubbed digits. 
This relationship was not formalized until almost a century later when Kennedy and 
Knudson (1997) described ‘hepatopulmonary syndrome’ as a clinicopathological 
entity characterized by hypoxemia and the pathogenetic hallmark of intrapulmonary 
vascular dilatations.
Severe hepatic dysfunction is not required and HPS can present in patients with 
mild liver disease (Abrams et al 1995).
This article reviews the clinical features, diagnostic modalities as well as current 
concepts regarding the pathogenesis of HPS. The evidence base to support pharma-
cological and nonpharmacological therapies is discussed.
Clinical manifestations
The clinical features of HPS are typically pulmonary manifestations. Dyspnea is the 
most common complaint and can be insidious in presentation. Platypnea deﬁ  ned as 
dyspnea exacerbated by sitting up and improved with lying down is a clinical feature 
of HPS. Orthodeoxia, deﬁ  ned as arterial deoxygenation accentuated in the upright 
position versus the supine position often accompanies platypnea and is highly speciﬁ  c Vascular Health and Risk Management 2008:4(5) 1036
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for HPS in the context of chronic liver disease (Seward et al 
1984). The cutoff value for orthodeoxia is delineated as a 
PaO2 decrease of 5% or more, or 4 mm Hg or more from the 
supine to upright position (Rolla et al 1997). The mechanism 
for orthodeoxia is attributed to preferential perfusion of the 
lung bases so that functional shunting is greater when the 
patient is upright (Robin et al 1976). Most patients will have 
stigmata of chronic liver disease on physical examination.
Alizadeh and colleagues (2006) reviewed 54 cirrhotic 
patients of which 10 (18.5%) and 7 cases (13%) had clinical 
and subclinical features of HPS, respectively. Dyspnea was a 
presenting feature of all patients with HPS and cyanosis was 
present in 90% of all cases. The presence of clubbing had 
the highest positive predictive value (75%) and dyspnea the 
highest negative predictive value (100%) for HPS.
Spider nevi are another common clinical feature of 
patients with HPS (Andrivet et al 1993; Lima et al 2004). 
Rodriguez-Roisin and colleagues (1987) noted that there 
was a signiﬁ  cant relationship between cutaneous spider 
angiomata and systemic and pulmonary vasodilatation 
suggesting that spider nevi may well represent a cutaneous 
marker for intrapulmonary vascular dilatations.
Natural history
The prognosis associated with HPS is poor. A prospective study 
of 27 patients with HPS showed that the presence of HPS is a 
major independent risk factor on the survival of patients with 
cirrhosis (Schenk et al 2003). In this study the median survival 
time in cirrhotic patients with HPS was 10.6 months compared 
to 40.8 months in cirrhotic patients without HPS. At an observa-
tion period of 2.5 years the mortality rate for HPS patients was 
approximately 63%. The leading cause of death was hemor-
rhagic shock secondary to gastrointestinal bleeding.
In a retrospective study of 22 patients with HPS the 
mortality rate was 41% after a mean time of 2.5 years after 
diagnosis (Krowka et al 1993).
The degree of arterial hypoxemia appears to inﬂ  uence 
survival. Swanson and colleagues (2005) demonstrated in a 
case-control study involving 61 HPS patients that long-term 
survival for HPS patients is worse in the subgroup with lower 
baseline PaO2 (50 mmHg).
Pathogenesis
The pathogenesis of HPS remains unknown. The hallmark 
of HPS is microvascular dilatation within the pulmonary 
arterial circulation. Microvascular dilatation impairs 
ventilation-perfusion matching and can produce anatomical 
and functional shunt physiology, leading to hypoxemia.
Early on some investigators believed that functional 
vasodilatation of the pulmonary vasculature was attributable 
to inadequate synthesis or metabolism of pulmonary 
vasoactive substances by a damaged liver (Bruix et al 1985; 
Krowka and Cortese 1990; Pizcueta et al 1992).
In the quest to deﬁ  ne the nature of these causal vasoactive 
substances, the potent vasodilator nitric oxide was identiﬁ  ed 
as a leading agent. Exhaled nitric oxide levels (a measure 
of pulmonary production) increase in cirrhotic patients with 
HPS and normalize after orthotopic liver transplantation 
(Cremona et al 1995; Rolla et al 1997). Overexpression of 
both endothelial nitric oxide synthase and inducible nitric 
oxide synthase are found in the pulmonary microcirculation 
(Fallon et al 1997; Nunes et al 2001).
Moreover one case report has revealed that inhibition of 
nitric oxide production with NG-LNAME transiently improves 
HPS with improvements in exercise tolerance and PaO2 
(Brussino et al 2003). Methylene blue – a dye that inhibits 
the effects of nitric oxide on soluble guanylate cyclase – was 
administered by a single intravenous dose in a small study of 
7 patients with HPS, established cirrhosis and a hyperdynamic 
circulatory state (Schenk et al 2000). These patients experi-
enced signiﬁ  cant improvements in gas exchange accompanied 
by an increase in pulmonary vascular resistance.
Intestinal endotoxemia with accompanying nitric oxide 
release and tumor necrosis factor (TNF)-α overproduction, 
secondary to enteral translocation of Gram-negative bacte-
ria due to portal hypertension has been proposed as a cause 
of excessive pulmonary vasodilatation (Zhang et al 2005). 
Improvements in arterial oxygenation have been recorded 
in HPS patients receiving antibiotic treatment (Rabiller 
et al 2002). Pentoxifylline, a nonspeciﬁ  c phosphodiesterase 
inhibitor that is recognized to block effects mediated by 
TNF-α in inﬂ  ammatory and endothelial cells, has been shown 
to markedly improve intrapulmonary vasodilatation and gas 
exchange abnormalities in rats without altering systemic or 
portal pressures (Zhang et al 2007).
Other studies have looked at the contribution of vasoac-
tive intestinal peptide, substance P, and atrial natriuretic 
factor as etiological agents in the process of pulmonary 
microvascular dilatation in cirrhosis (Henriksen et al 1980; 
Hortnagl et al 1984; Gines et al 1988).
Vasodilatation alone however is not thought to be 
responsible for the pathobiological process in HPS. A recent 
study found that while administration of inhaled L-NAME 
in ten HPS patients did attenuate systemic and pulmonary 
vasodilatation, V/Q mismatch and arterial hypoxemia did 
not improve (Gomez et al 2006).Vascular Health and Risk Management 2008:4(5) 1037
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This study goes on to suggest that arterial deoxygenation 
in HPS is unlikely to be due to an ongoing vasodilator effect 
from enhanced pulmonary nitric oxide production.
Indeed vasodilatation alone is unlikely to account for the 
more than 10-fold increase in capillary diameters in HPS 
especially as there is little smooth muscle to relax in normal 
capillaries (Naeijie and Dinh-Xuan 2005).
A new concept has emerged that the pulmonary 
microcirculation in patients with cirrhosis may manifest 
through decreased hypoxic pulmonary vascular constriction 
accompanied by a vasoconstrictive release leading to dilata-
tion (Naeijie et al 1981, Gomez et al 2006). A key goal of 
research in HPS is to establish how such pulmonary vascular 
changes relate to the systemic vasodilatation which underlies 
the hyperdynamic circulatory and neuroregulatory dysfunc-
tion state seen in cirrhotic patients.
Mechanisms of hypoxemia
Intrapulmonary vascular dilatations especially in alveolar 
regions, are the deﬁ  ning pathological hallmark of HPS and 
are thought to be responsible for hypoxemia (Davis et al 
1978; Edell et al 1989). Rydell and Hoffbauer (1956) ﬁ  rst 
documented the presence of numerous intrapulmonary arte-
riovenous anastomoses in their postmortem report of a patient 
with juvenile cirrhosis and cyanosis. This ﬁ  nding in cirrhotic 
patients was conﬁ  rmed radiologically through injections of 
micro-opaque gelatin to show widespread dilation of the 
pulmonary vasculature at precapillary and capillary levels 
(Berthelot et al 1966).
The normal diameter of capillaries in the alveolar sep-
tum is 7–15 microns (Davis et al 1978) and particles larger 
than 15 microns are normally trapped in the pulmonary 
vasculature. Several studies used intravenous radiolabeled 
macroaggregated albumin particles larger than 20 microns 
in diameter to establish the presence of dilated pulmonary 
microvasculature as these particles were shown to traverse 
the pulmonary vasculature and enter systemic circulation 
(Robin et al 1975; Genovesi et al 1976; Wolfe et al 1977). 
Intrapulmonary capillary dilatations as large as 500 microns 
in diameter have been found (Williams et al 1979).
In a true anatomical shunt hypoxemia persists despite 
100% oxygen inhalation. Supplementary oxygen however 
does improve oxygenation in HPS and is a recommended 
treatment for HPS. A hypothesis has been developed to 
account for the mechanisms of hypoxemia in HPS known 
as the alveolar-capillary oxygen disequilibrium (Davis et al 
1978). This hypothesis proposes that when the capillary is 
grossly dilated, oxygen molecules from adjacent alveoli are 
unable to permeate sufﬁ  ciently to the center of the dilated 
vessel. It is the center of the vessel that tends to contain the 
stream of erythrocytes carrying hemoglobin and thus inad-
equate oxygenation of hemoglobin leads to systemic hypox-
emia. This diffusion defect is able to be partially overcome 
by the use of supplementary oxygen.
It is now evident that intrapulmonary vascular dilatations 
can occur in one of two patterns (Krowka and Cortese 1990). 
The more common Type I lesions are characterized by dif-
fuse pulmonary vascular dilatations at the precapillary level 
close to the normal gas exchange units of the lung whereas 
Type II lesions are more discrete, localized dilatations and are 
actually large arteriovenous communications distant from the 
gas exchange units. Supplementary oxygen improves Type 
I HPS PaO2 but Type 2 HPS has a poor response to oxygen 
as true anatomical shunting is present.
The fraction of total cardiac output conducted by intra-
pulmonary vascular dilations can be as high as 70% (Wolfe 
et al 1977). This increased cardiac output reduces transit 
time through the low-resistance pulmonary vasculature and a 
decrease in intrapulmonary transit time contributes to hypox-
emia. Exercising patients with HPS can shorten transit time 
and worsen oxygenation through the formation of a greater 
functional shunt (Thorens and Junod 1992).
Diagnosis
In the evaluation of the hypoxemic cirrhotic patient the exclu-
sion of other contributing cardiopulmonary causes such as 
pulmonary atelectasis, ascites, chronic obstructive pulmonary 
disease, and hepatic hydrothorax is mandatory. A careful 
history and physical examination aids in the consideration 
of alternative diagnoses of dyspnea.
An arterial blood gas analysis to detect hypoxemia is 
the next investigation of choice. Schenk and colleagues 
(2002) noted the difﬁ  culty of setting arbitrary cut-off values 
for hypoxemia in published studies. The use of different 
cut-off values deﬁ  ning arterial hypoxemia in studies led to 
a wide range of prevalence rates for HPS in patients with 
cirrhosis. Their study showed that arterial hypoxemia deﬁ  ned 
as a PaO2 70 mmHg or below the age-related threshold 
predicted the presence of HPS with high probability in the 
absence of intrinsic cardiopulmonary diseases.
If gas exchange abnormalities are detected chest 
radiography and pulmonary function tests can be used to help 
rule out other cardiopulmonary abnormalities.
However, even in the presence of chronic cardiopulmo-
nary conditions the diagnosis of HPS can be made if there 
is evidence of pulmonary vasodilatation with demonstrable Vascular Health and Risk Management 2008:4(5) 1038
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functional shunting. This can be achieved by means of 
contrast echocardiography using intravenous injections of 
agitated saline or indocyanine green to produced bubbles 
of at least 15 microns in diameter (Kamath 2002). Under 
normal circumstances these microbubbles are trapped in the 
pulmonary vasculature and absorbed. However in the pres-
ence of intracardiac right to left shunts, these microbubbles 
are seen in the left heart within the ﬁ  rst three cardiac cycles 
(Shub et al 1976). In hepatopulmonary syndrome, the bubbles 
are seen in the left heart after the third heart beat, usually 
between the third and sixth heart beat.
Much work has focused on echocardiographic examina-
tion in the evaluation of HPS. For instance a measured maxi-
mal left atrial volume 50 ml has been shown recently to be 
a simple and feasible parameter to detect HPS in cirrhotic 
patients (Zamirian et al 2007). Right ventricular diastolic 
dysfunction is notably more common in cirrhotic patients 
with HPS than cirrhotic patients without HPS (Karabulut 
et al 2006). Vedrinne and colleagues (1997) found that 
transesophageal echocardiography using gelatin contrast 
solution to be a more sensitive test than transthoracic echo-
cardiography with an intrapulmonary shunt detection rate of 
51% compared to 32%.
There are however a number of limitations of contrast-
enhanced echocardiography (Wang and Lin 2005). Most 
notably contrast-enhanced echocardiography cannot quantify 
the degree of intrapulmonary shunting. It is also unable to 
differentiate between intrapulmonary vascular dilatation 
and direct arteriovenous communication. Finally speciﬁ  city 
is lacking as there are cirrhotic patients with a positive 
echocardiographic study that have normal arterial blood gas 
proﬁ  les and thus do not meet the deﬁ  nition of HPS (Hopkins 
et al 1992).
99Technetium macroaggregated albumin perfusion 
lung scanning overcomes the first limitation of contrast 
echocardiography as it permits quantiﬁ  cation of the degree of 
intrapulmonary shunting (Abrams et al 1998). In perfusion lung 
scanning albumin macroaggregates 20 microns in diameter 
are normally entrapped in pulmonary vasculature but in patients 
with intracardiac/intrapulmonary shunts these particles are able 
to enter systemic circulation and are taken by other organs in the 
body. Normally, less than 5% of the isotope can be quantitated 
over the brain. In hepatopulmonary syndrome, there is 6% 
uptake in the brain. The major disadvantage of the 99Technetium 
macroaggregated albumin scan is that it cannot differentiate 
intracardiac from intrapulmonary shunting.
Contrast enhanced cardiography has been shown to 
be more sensitive than lung perfusion scanning for the 
detection of intrapulmonary vascular dilatations (Abrams 
et al 1995). It has the additional advantage in that it can be 
performed as part of routine echocardiographic screening 
for pulmonary hypertension and the European Respiratory 
Society Task Force on Pulmonary-Hepatic vascular disorders 
has recommended contrast-enhanced echocardiography as 
the ﬁ  rst line screening modality for HPS (Rodriguez-Roisin 
et al 2004).
Pulmonary angiography is reserved for those patients who 
have a poor response to 100% oxygen, demonstrated by an 
increase in the PaO2 to less than 300 mmHg (Kamath 2002). 
It is an invasive procedure that can delineate the appearance 
of the pulmonary vasculature. There are 2 patterns seen with 
pulmonary angiography: Type 1 HPS as characterized by pre-
capillary pulmonary artery dilatation without arteriovenous 
ﬁ  stulas and Type 2 HPS where localized pulmonary arterio-
venous ﬁ  stulous communications are seen (Scott et al 1999; 
Ryu and Oh 2003). Type 1 angiographic ﬁ  ndings can vary 
from normal to an advanced diffuse ‘spider-like’ or spongy 
appearance (Krowka et al 1993; Castro and Krowka 1996). 
These Type 1 HPS patients with advanced diffuse pulmonary 
changes have more severe hypoxemia and respond poorly to 
100% oxygen (Krowka et al 1993).
Type 2 HPS which is less common, does not respond to 
100% oxygen with partial pressure measurements generally 
not exceeding 200 mm Hg with 100% oxygen (Scott et al 
1999). Patients with Type 2 HPS should be considered for 
embolotherapy although there are case reports of coil emboli-
zation in Type 1 HPS used as a temporizing measure prior to 
liver transplantation (Ryu and Oh 2003; Saad et al 2007).
Remodeling of the pulmonary vasculature does occur 
after liver transplantation although the time taken for this 
to occur is variable, in some cases over a year (Fallon and 
Abrams 2000).
Management
Many pharmacological treatments have been trialed in the 
management of HPS. Ostensibly such treatments target the 
putative mediators of HPS such as nitric oxide and TNF-α 
although quite often pharmacological agents are tried with 
no substantive physiological basis.
Nitric oxide antagonists such as NG-nitro-L-arginine-
methylester (L-NAME) and methylene blue as described 
previously have been trialed with variable improvements 
in gas exchange (Schenck et al 2000; Brussino et al 2003). 
Somatostatin analogues, cyclooxygenase inhibitors, and 
immunosuppressive agents such as glucocorticoids and 
cyclophosphamide have been trialed with mixed and more Vascular Health and Risk Management 2008:4(5) 1039
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often disappointing results (Shijo et al 1991; Krowka et al 
1993; Soderman et al 1994; Cadranel et al 1992).
Almitrine bimesylate a selective pulmonary vasocon-
strictor was thought to be a promising agent for HPS as in 
theory via its vasoconstrictive effect it may lower physiolog-
ical shunting and thereby reduce existing diffusion defects. 
It has had notable success in isolated case reports (Milhe 
et al 2006) however Krowka and Cortese (1987) found that 
only 1 of the 5 patients receiving almitrine bismesylate in 
their pilot study had any improvement in oxygenation and 
that the magnitude of this response was small (10 mm Hg 
increase in PaO2 on breathing room air). In another study 
almitrine bismesylate failed to produce a signiﬁ  cant increase 
in PaO2 in 6 patients with HPS (Nakos et al 1993).
Interestingly, the use of garlic powder capsules daily for 
a minimum of 6 months resulted in a modest improvement 
in arterial oxygenation in 6 out of 15 subjects in a small pilot 
trial (Abrams and Fallon 1998).
Antibiotic treatment has resulted in improvements in 
arterial oxygenation in HPS patients (Rabiller et al 2002). The 
nonspeciﬁ  c phosphodiesterase inhibitor pentoxifylline that 
is a recognized TNF-α blocker has been shown to improve 
intrapulmonary vasodilatation and gas exchange abnormali-
ties, but this is demonstrable only in animal studies (Zhang 
et al 2007). A phase 1 open-label pilot study of pentoxifylline 
in humans with HPS was recently terminated because of poor 
tolerability and substantial side effects (NIH 2008).
A case report of the vasodilator Iloprost describes a 
beneﬁ  t in the reduction of hypoxia, dyspnea and an increase 
in exercise capacity mediated possibly through widespread 
dilation of pulmonary capillaries with ensuing decreased 
pulmonary shunting and increased transit time of erythryo-
cytes (Krug et al 2007).
The limitation with the evidence base to date for 
pharmacological treatment in HPS is that data is presented 
through either case reports or small, uncontrolled trials that 
lack sufﬁ  cient size to test for efﬁ  cacy. Randomized controlled 
trials with sufﬁ  cient sample sizes are required to investigate 
new pharmacological interventions.
The development of portal hypertension is thought to 
play a key role in the pathogenesis of HPS. A reduction 
in portal pressure appears to be beneﬁ  cial in HPS and a 
few case reports (Allgaier et al 1995; Riegler et al 1995; 
Selim et al 1998) have documented variable improvements 
in gas exchange with the use of transjugular intrahepatic 
portosystemic shunts (TIPS). However a more recent study 
involving 3 patients with HPS the use of TIPS did not lead 
to any overall sustained change in arterial blood gas proﬁ  le 
(Martinez-Palli et al 2005) and there is currently insufﬁ  cient 
evidence to support TIPS as a recommended treatment in 
HPS.
Other radiological interventional procedures have been 
trialed in HPS. Percutaneous transluminal balloon cavalo-
plasty is an effective treatment in patients with suprahepatic 
inferior vena cava (IVC) obstruction (Yamada et al 1983). 
HPS sometimes occurs in cases of IVC obstruction and in 
one report a patient with HPS and IVC obstruction after 
undergoing balloon cavaloplasty experienced signiﬁ  cant 
improvement in dyspnea, cyanosis, and hypoxemia, with 
intrapulmonary shunt reversal (De et al 2000). In a follow-
up study, De and colleagues (2002) showed an impressive 
intrapulmonary shunt reversal in 5 out of 6 cases.
Type 2 HPS as noted previously is characterized by 
pulmonary arteriovenous ﬁ  stulas and does not respond well 
to oxygen therapy. Transcatheter coil embolization of the 
arteriovenous pulmonary ﬁ  stulas in type 2 HPS has been 
successful in reducing morbidity of HPS before and after 
liver transplantation (White et al 1988; Poterucha et al 1995). 
Embolotherapy may be a reasonable ﬁ  rst line of bridging 
therapy in patients with Type 2 HPS prior to transplantation. 
Even in Type 1 patients with advanced diffuse pulmonary 
changes, beneﬁ  ts in reducing morbidity pre-transplantation 
have been described with coil embolization (Ryu and Oh 
2003; Saad et al 2007).
An important therapy for HPS is oxygen supplementation 
which does lead to signiﬁ  cant improvements in hypoxemia. 
Long-term supplementary oxygenation thus is advised in 
all hypoxemic HPS patients despite the lack of data to show 
improvements in survival.
The only deﬁ  nitive treatment for HPS is orthotopic liver 
transplantation. The data to support this is incontrovertible 
although the mechanism of how the pulmonary vasculature 
is remodeled after transplantation is not clearly understood. 
What is known is that at least 85% of all cases of patients 
with HPS undergoing liver transplantation experience either 
signiﬁ  cant improvement or complete resolution in hypoxemia 
(Lange and Stoller 1996). This resolution however may take 
time and in some cases over a year (Fallon and Abrams 
2000). Unfortunately the mortality after liver transplanta-
tion is signiﬁ  cantly increased in HPS patients with a 1-year 
survival rate of 71% noted in one cohort study (Arguedas et al 
2003). Survival is worse for those patients with more severe 
hypoxemia and signiﬁ  cant intrapulmonary shunting.
The understanding that orthotopic liver transplantation 
provides the best and often complete management of HPS 
has revolutionized the therapeutic approach to this unique Vascular Health and Risk Management 2008:4(5) 1040
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disease entity. No longer is hypoxemia in such patients 
considered a relative contraindication for transplantation. 
In fact the degree of hypoxemia is considered critical in the 
consideration for liver transplantation. The ERS Task Force 
on Pulmonary-Hepatic Vascular Disorders recommends 
as a ﬁ  rm indication for orthotopic liver transplantation if 
PaO2 50–60 mmHg and consideration of orthotopic liver 
transplantation on an individual basis if PaO2 50 mmHg 
(Rodriguez-Roisin et al 2004).
As no other accepted medical therapy exists at the present 
time for HPS other than supplementary oxygen, proceeding 
with orthotopic liver transplantation in suitable HPS patients 
is the best step forward.
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